KZA kazia therapeutics limited

Kazia Posts Interim Data From Paxalisib Combo Study In Brain...

  1. 6,853 Posts.
    lightbulb Created with Sketch. 2539
    Kazia Posts Interim Data From Paxalisib Combo Study In Brain Metastases

    Kazia Therapeutics Limited

    KZIA+4.79%+ Free Alerts
    announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with radiotherapy for brain metastases.
    Interim data from the first stage of the study reports that all nine evaluable patients experienced a complete or partial response, representing an overall response rate (ORR) of 100%.
    The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials. A maximum tolerated dose (MTD) of 45mg daily combined with radiotherapy was confirmed.
    Shares are up 31.8% at $2.34 during the market session.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.